Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total transaction of $263,588.40. Following the sale, the chief financial officer owned 51,000 shares of the company’s stock, valued at approximately $2,233,800. This represents a 10.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics Trading Up 5.7%

Enliven Therapeutics stock opened at $48.60 on Wednesday. The stock has a 50 day moving average of $41.89 and a two-hundred day moving average of $31.96. Enliven Therapeutics, Inc. has a twelve month low of $14.78 and a twelve month high of $48.79. The stock has a market capitalization of $2.96 billion, a price-to-earnings ratio of -29.10 and a beta of 0.29.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. Equities analysts predict that Enliven Therapeutics, Inc. will post -1.71 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on ELVN. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Guggenheim assumed coverage on Enliven Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $80.00 price target on the stock. Stifel Nicolaus began coverage on shares of Enliven Therapeutics in a report on Tuesday, June 9th. They set a “buy” rating and a $60.00 price objective for the company. Mizuho increased their target price on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Finally, The Goldman Sachs Group increased their price objective on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $63.40.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ELVN. KBC Group NV bought a new stake in shares of Enliven Therapeutics in the 1st quarter worth approximately $38,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after buying an additional 594 shares during the period. BNP Paribas Financial Markets grew its stake in Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in Enliven Therapeutics in the 4th quarter valued at approximately $83,000. Finally, Quantbot Technologies LP lifted its position in Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.